|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||48.90 - 53.12|
|52 Week Range||34.88 - 277.80|
|Beta (5Y Monthly)||1.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||155.17|
(Bloomberg) -- Whether it’s commendable courage or a refusal to face reality, a receding stock market tide has left Wall Street analysts sitting with price predictions that will take more than a little luck to come true.Most Read from BloombergTrump’s Final Scene Didn’t Go According to ScriptDemocrats Weigh Paring Biden Tax Hike to Win Over ManchinVenice Plans to Start Weeding Out Cheap TouristsFauci Suffers Covid Symptom Rebound After Course of Pfizer’s PaxlovidDisquiet Over the Housing Market
Taiwan will take delivery of its first doses of the Novavax Inc COVID-19 vaccine this week, received under the COVAX sharing scheme, the government said on Wednesday. Taiwan's Central Epidemic Command Centre said the 504,000 doses would arrive on Thursday at Taipei's main international airport. Taiwan is scheduled to receive 2.268 million doses of the Novavax vaccine in batches this year through the COVAX mechanism, it added.
Novavax (NASDAQ: NVAX) is a pandemic stock. Now it's down to $50, and the company's market cap is under $4 billion. Here are three arguments for buying Novavax stock and one reason for why you might want to avoid these shares.